Ben Glicksberg

Scientific Advisor at Character Bio

Ben Glicksberg's work experience includes various roles in the biosciences field. Ben is currently serving as the Vice President of Data Science and Machine Learning at Character Biosciences since June 2022. Previously, they worked as a Consultant and Scientific Advisor at Prometheus Biosciences, Inc. from August 2021 to June 2022. From October 2019 to June 2022, they were an Assistant Professor at the Icahn School of Medicine at Mount Sinai. Ben also worked as a Visiting Research Scientist at Sheba Tel HaShomer City of Health in April 2022. Ben served as an Adjunct Faculty at Hasso Plattner Institute from October 2020 to May 2022. Ben worked as a Consultant at Sema4 from January 2019 to October 2019. Ben's experience also includes being a Postdoctoral Scholar at the University of California, San Francisco from September 2017 to October 2019. Ben worked as a Consultant at Data2Discovery Inc from June 2018 to June 2019. Additionally, they served as a Graduate Student at the Icahn School of Medicine at Mount Sinai from an unspecified date in 2012 to September 2017. Lastly, they worked as a Bioinformatics Research Intern at IBM from June 2016 to September 2016.

Ben Glicksberg completed their Bachelor of Arts degree in Neuroscience at Skidmore College from 2006 to 2010. Ben pursued further education at the Icahn School of Medicine at Mount Sinai, where they obtained their Doctor of Philosophy (Ph.D.) in Neurobiology and Neurosciences between 2012 and 2017. Following this, they engaged in a post-doctorate program at the University of California, San Francisco, specializing in Clinical Informatics from 2017 to 2019.

Location

Brooklyn, United States

Links

Previous companies


Org chart


Teams


Offices

This person is not in any offices


Character Bio

Character partners with patients, providers, payers, and scientists to create deeply-phenotyped patient cohorts to enable clinical genomic research. Our approach integrates genomics, longitudinal clinical and imaging data, machine learning, and novel experimental approaches to identify the molecular drivers of disease progression and develop innovative targeted medicines.


Employees

11-50

Links